North America Superdisintegrants Market

North America Superdisintegrants Market Size (2023 to 2028)

The size of the Superdisintegrants Market in North America is estimated at USD 137.41 million in 2023. This value is estimated to be growing at a CAGR of 7.15% to reach USD 191.09 million by 2028.

Y-O-Y growth in the neurological disorders and advantages associated with the generic drugs are expected to boost the market growth in North America. The pharmaceutical industry's growing attention as they mount the solubility of active pharmaceutical ingredients, high manufacturing rate of tablets are to propel the market in North America. Wide utilization of these superdisintegrants among massive pharmaceutical drug formations is another significantly contributing to market growth. The focus on R&D developing new drugs is estimated to favor the Superdisintegrants market in North America. The development of viruses, bacteria, and parasites associated with the increasing acquisition of unhealthy lifestyles, genetic disorders, and improper diet intake are to escalate the growth of the market during the forecast period.

The High costs involved and lengthy approval time taken by the U.S. FDA to accept the new drugs are expected to slow down the market growth to a small extent.

This research report on the North America Superdisintegrants Market has been segmented and sub-segmented into the following categories:

• By Product Type: Natural Superdisintegrants and Synthetic Superdisintegrants.
• By Application: Capsules and Tablets.
• By Therapeutic Area: Gastrointestinal diseases, Neurological diseases, Oncology, Infectious Diseases, Cardiovascular Diseases, Hematological diseases, and Inflammatory Diseases
• By Country: The United States, Canada, and Rest of North America

Regional Analysis:

North America is estimated to rule in the global market during the forecast period due to the growing demand for superdisintegrants, cost-effectiveness, palatability and ease of administration, and flexibility in large and small molecules.

The USA is leading the market while Canada is in second place. Increasing financial support for the development of innovative oral dosage forms and constant effort devoted towards providing superior quality and compliant products in the market are the primary factors responsible for the dominance of the USA.

The USA is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure, and awareness.

Promising Companies dominating the North America Superdisintegrants Market Profiled in the Report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co., and Huber Corporation.